Dive into the archives.
- Hot off the ECTRIMS Press: Peptimmune Completes Ph 1b Study of PI-2301
Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
CAMBRIDGE, Mass., Aug. 25 /PRNewswire/ — Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is [...]
- Product Overview – DIRUCOTIDE
Product Overview – DIRUCOTIDE
Dirucotide (formally named MBP8298) is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein (MBP). Dirucotide has been developed for the treatment of multiple sclerosis (specifically secondary progressive MS) and is based on over 26 years of [...]
- SPMS Treatment Update: Spotlight on dirucotide (BioMS Medical Corp.)
BioMS Medical Announces 2008 Year End Results
Edmonton, Alberta, March 17, 2009 – BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the year ended December 31, 2008.
“Dirucotide has demonstrated the ability to safely affect MS progression in previous studies and we look [...]
